Merck (MRK) is back in focus after a busy early August, as Q2 results, a guidance update, fresh product approvals and new regulatory milestones for ENFLONSIA and KEYTRUDA put the stock’s recent run into context.

Merck’s recent guidance tweak, ENFLONSIA sBLA progress and KEYTRUDA label expansion news sit alongside strong momentum in the stock, with a year to date share price return of 27.34% and a five year total shareholder return of 101.93%. This suggests that investors are reassessing both growth potential and risk around the pipeline.

If Merck’s run has you thinking about where else growth stories could come from in healthcare, it may be worth scanning other companies building next generation treatments through the 44 healthcare AI stocks

Bulls point to Merck’s raised revenue guidance, ENFLONSIA momentum and fresh KEYTRUDA approvals. Bears focus on current losses, higher expenses and patent risk. Which side do the current valuation markers appear to favor at this point?

Most Popular Narrative: 1% Undervalued

Merck last closed at $135.55 compared with a narrative fair value anchor of $136.85, which keeps the focus squarely on whether the earnings blueprint behind that figure holds up.

With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth.

Want to see what turns that enlarged pipeline into today’s fair value number? The narrative leans on measured revenue growth, sharply higher margins and a future earnings multiple that assumes Merck’s portfolio mix looks very different a few years from now.

Result: Fair Value of $136.85 (UNDERVALUED)

However, the Merck narrative still hinges on KEYTRUDA’s eventual loss of exclusivity, as well as any regulatory or pricing shifts that could pressure revenue and margins.

Another View: What Merck’s High P/E Ratio Signals

Our DCF model points to Merck trading below an estimated fair value, yet the current P/E ratio of 105.4x is far above the US Pharmaceuticals industry average of 16.6x, the peer average of 29.9x, and a fair ratio of 44.8x. That gap suggests investors face real valuation risk if expectations reset.

To see how this pricing picture fits with the full earnings and cash flow story, it is worth stepping through the detailed valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both optimism and concern around Merck in this article, it makes sense to check the numbers for yourself and move quickly. To weigh those cross currents for your own portfolio, start with the 2 key rewards and 5 important warning signs

Looking for more ideas beyond Merck?

If Merck has sharpened your focus on finding the next opportunity, do not stop here. Use the Simply Wall St screener to pressure test your own watchlist.

• Target potential long term value by checking companies that stand out on quality and valuation through the 51 high quality undervalued stocks
• Strengthen your income stream by reviewing companies with higher yields through the 11 dividend fortresses
• Prioritise resilience by scanning companies with lower risk profiles using the 88 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.